US 11,703,511 B2
Anti-isoAsp7 amyloid β (Aβ) antibodies and uses thereof
Anke Piechotta, Halle (DE); Kathrin Gnoth, Halle (DE); Holger Cynis, Halle (DE); Jens-Ulrich Rahfeld, Seegebiet Mansfelder Land (DE); Stephan Schilling, Halle (DE); and Hans-Ulrich Demuth, Halle (DE)
Assigned to FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., Munich (DE)
Appl. No. 16/632,289
Filed by FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., Munich (DE)
PCT Filed Jul. 17, 2018, PCT No. PCT/EP2018/069404
§ 371(c)(1), (2) Date Jan. 17, 2020,
PCT Pub. No. WO2019/016213, PCT Pub. Date Jan. 24, 2019.
Claims priority of application No. 17182167 (EP), filed on Jul. 19, 2017.
Prior Publication US 2020/0264197 A1, Aug. 20, 2020
Int. Cl. C07K 16/18 (2006.01); C07K 16/44 (2006.01); A61K 39/395 (2006.01); G01N 33/68 (2006.01); G01N 33/543 (2006.01)
CPC G01N 33/6896 (2013.01) [A61K 39/39583 (2013.01); C07K 16/18 (2013.01); C07K 16/44 (2013.01); G01N 33/543 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
OG exemplary drawing
 
1. An antibody or antigen-binding fragment thereof which specifically binds to L-isoAsp7 amyloid β (Aβ), wherein the KD of the interaction between the antibody and SEQ ID NO: 44 is at least 10 times less than the KD of the interaction between the antibody and SEQ ID NO: 8 and the KD is determined by surface plasmon resonance at 25° C.
and wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region (VL) and a heavy chain variable region (VH), wherein said VL comprises LCDR1, LCDR2 and LCDR3 polypeptides and VH comprises HCDR1, HCDR2 and HCDR3 polypeptides which are selected from the group consisting of:
(a) LCDR1 is KSSQSLLNSRNRKNYLA (SEQ ID NO: 9), LCDR2 is WASTRDS (SEQ ID NO: 11), LCDR3 is KQSYNLRT (SEQ ID NO: 13), HCDR1 is GFSLTSYGVH (SEQ ID NO: 14), HCDR2 is ALWASGNTDYSSTLMS (SEQ ID NO: 15), and HCDR3 is DRGILTGGYFDV (SEQ ID NO: 17);
(b) LCDR1 is KSSQSLFNSRTRKNYVA (SEQ ID NO: 27), LCDR2 is WASTRES (SEQ ID NO: 29), LCDR3 is KQSYNLRA (SEQ ID NO: 30), HCDR1is GFTFTDYYMS (SEQ ID NO: 32), HCDR2 is FIRNKANGYTTEYSASVKG (SEQ ID NO: 34), and HCDR3 is DIPTIMDY (SEQ ID NO: 35);
(c) LCDR1 is KSSQSLLNX1RX2RKNYLA (SEQ ID NO: 10), LCDR2 is WASTRX3S (SEQ ID NO: 12), LCDR3 is KQSYNLRT (SEQ ID NO: 13), HCDR1 is GFSLTSYGVH (SEQ ID NO: 14), HCDR2 is X4LWASGX5TDYX6SX7LMS (SEQ ID NO: 16), and HCDR3 is DRGIX8TGGYFDV (SEQ ID NO: 18), wherein X1 is S or R, X2 is N or T, X3 is D or E, X4 is A or V, X5 is N or R, X6 is S or N, X7 is T or A, and X8 is L, T or M; and
(d) LCDR1 is KSSQX1LX2NSRTRKNYX3A (SEQ ID NO: 28), LCDR2 is WASTRES (SEQ ID NO: 29), LCDR3 is X4QSYNLRX5 (SEQ ID NO: 31), HCDR1 is GFTFX6DYYMX7 (SEQ ID NO: 33), HCDR2 is FIRNKANGYTTEYSASVKG (SEQ ID NO: 34), and HCDR3 is DIPTIMDY (SEQ ID NO: 35), wherein X1 is S or N, X2 is F or L, X3 is V or L, X4 is K or M, X5 is A or T, X6 is T or S, and X7 S or N.